The diagnosis and treatment of generalized anxiety disorder

Primary Psychiatry

Volumn 12, Issue 11, 2005, Pages 58-67

  Schulz, Julie ^a   Gotto, Jennifer G ^a   Rapaport, Mark H ^a,b  

^a CEDARS SINAI MEDICAL CENTER   (United States)

^b UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

4 AMINOBUTYRIC ACID A RECEPTOR; ALPRAZOLAM; BENZODIAZEPINE DERIVATIVE; BENZODIAZEPINE RECEPTOR; BUSPIRONE; CHLORDIAZEPOXIDE; CLONAZEPAM; CORTICOTROPIN RELEASING FACTOR; DIAZEPAM; DOPAMINE; ESTAZOLAM; FLURAZEPAM; HYDROXYZINE; KAVA; LORAZEPAM; MIRTAZAPINE; MONOAMINE OXIDASE INHIBITOR; NEFAZODONE; NEUROTRANSMITTER; NORADRENALIN; OXAZEPAM; SEROTONIN; SEROTONIN UPTAKE INHIBITOR; TEMAZEPAM; TRAZODONE; TRIAZOLAM; TRICYCLIC ANTIDEPRESSANT AGENT; TYRAMINE; UNINDEXED DRUG; VENLAFAXINE;

ANORGASMIA; BEHAVIOR THERAPY; CARDIOVASCULAR SYMPTOM; CLINICAL FEATURE; CLINICAL TRIAL; COGNITIVE THERAPY; COMORBIDITY; CONCENTRATION LOSS; CONSTIPATION; DIARRHEA; DISEASE COURSE; DRUG ABSORPTION; DRUG EFFICACY; DRUG HALF LIFE; DRUG MECHANISM; DRUG POTENCY; EXERCISE; FAMILY; FATIGUE; FUNCTIONAL DISEASE; GASTROINTESTINAL SYMPTOM; GENERALIZED ANXIETY DISORDER; HEALTH CARE COST; HEALTH CARE UTILIZATION; HUMAN; HYPOTHALAMUS HYPOPHYSIS ADRENAL SYSTEM; MAJOR DEPRESSION; MUSCULOSKELETAL DISEASE; NAUSEA; PREVALENCE; PRIMARY MEDICAL CARE; PSYCHODYNAMICS; PSYCHOMOTOR DISORDER; PSYCHOPHARMACOTHERAPY; PSYCHOTHERAPY; QUALITY OF LIFE; REMISSION; RESTLESSNESS; REVIEW; SIDE EFFECT; SOMNOLENCE; SYMPTOM; VISUAL IMPAIRMENT; WEIGHT GAIN; WORK; XEROSTOMIA;

EID: 28544433247     PISSN: 10826319     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (97)

1. DuPont RL, Rice DP, Miller LS, Shiraki SS, Rowland CR, Harwood HJ. Economic costs of anxiety disorders. Anxiety. 1996;2(4):167-172.
2. Kessler RC, McGonagle KA, Zhao S, et al. Lifetime and 12-month prevalence of DSM-III-R psychiatric disorders in the United States. Results from the National Comorbidity Survey. Arch Gen Psychiatry. 1994;51(1):8-19.
3. Weiner H. The psychobiology and pathophysiology of anxiety and tear. In: Tuma AH, Maser J, eds. Anxiety and the Anxiety Disorders. Hillsdale, NJ: Lawrence Erlbaum; 1985:333-345.
4. First MB, Spitzer RL, Gibbon M, Williams J. Structured Clinical Interview for DSM-IV Axis I Disorders, Clinician Version (SCID-CV). Washington, DC: American Psychiatric Press; 1997.
5. Ballenger JC, Davidson JR, Lecrubier Y, et al. Consensus statement on generalized anxiety disorder from the International Consensus Group on Depression and Anxiety. J Clin Psychiatry. 2001;62(suppl 11):53-58.
6. Posternak MA, Zimmerman M. Short-term spontaneous improvement rates in depressed outpatients. J Nerv Ment Dis. 2000;188(12):799-804.
7. Fifer SK, Mathias SD, Patrick DL, Mazonson PD, Lubeck DP, Buesching DP. Untreated anxiety among adult primary care patients in a health maintenance organization. Arch Gen Psychiatry. 1994;51(9):740-750.
8. Sareen J, Houlahan T, Cox BJ, Asmundson GJ. Anxiety disorders associated with suicidal ideation and suicide attempts in the National Comorbidity Survey. J Nerv Ment Dis. 2005;193(7):450-454.
9. Diagnostic and Statistical Manual of Mental Disorders, 3rd ed. Washington, DC: American Psychiatric Association; 1980.
10. Blazer DG, Hughes D, George LK, et al. Generalized anxiety disorder. In: Robins LN, Reiger DA, eds. Psychiatric Disorders in America: The Epidemiologic Catchment Area Study. New York, NY: The Free Press; 1990:180-203.
11. Diagnostic and Statistical Manual of Mental Disorders, 4th ed. Washington, DC: American Psychiatric Association; 1994.
12. Kessler RC, Berglund P, Demler O, Jin R, Merikangas KR, Walters EE. Lifetime prevalence and age-of-onset distributions of DSM-IV disorders in the National Comorbidity Survey Replication. Arch Gen Psychiatry. 2005;62(6):593-602.
13. Wittchen HU, Nelson CB, Lachner G. Prevalence of mental disorders and psychological impairments in adolescents and young adults. Psychol Med. 1998;28(1):109-206.
14. Carter RM, Wittchen HU, Plister H, Kessler RC. One-year prevalence of subthreshold and threshold DSM-IV generalized anxiety disorder in a nationally representative sample. Depress Anxiety. 2001;13(2):78-88.
15. Ustun TB, Sartorius N (eds). Mental Illness in General Health Care: An International Study. New York, NY: John Wiley & Sons; 1996:18-23.
16. Olfson M, Broadhead WE, Weissman MM, et al. Subthreshold psychiatric symptoms in a primary care group practice. Arch Gen Psychiatry. 1996;53(10):880-886.
17. Wittchen HU, Krause P, Hoyer J, et al. Prevalence and correlates of generalized anxiety disorders in primary care. Fortschr Med Orig. 2001;1999(suppl 1):17-25.
18. Wittchen HU, Zhao S, Kessler RC, et al. DSM-III-R generalized anxiety disorder in the National Comorbidity Survey. Arch Gen Psychiatry. 1994;51(5):355-364.
19. Noyes R Jr. Comorbidity in generalized anxiety disorder. Psychiatr Clin N Am. 2001;24(1):41-55.
20. Sanderson WC, Barlow DH. A description of patients diagnosed with DSM-III-R generalized anxiety disorder. J Nerv Ment Dis. 1990;178:588-581.
21. Brown TA, Barlow DH. Comorbidity among anxiety disorders: implications for treatment and DSM-IV. J Consult Clin Psychol. 1992;60(6):835-844.
22. Noyes R Jr, Woodman C, Garvey MJ, el al. Generalized anxiety disorder vs. panic disorder. Distinguishing characteristics and patterns of comorbidity. J Nerv Ment Dis. 1992;180(6):369-379.
23. Brawman-Mintzer O, Lydiard RB, Emmanuel N, et al. Psychiatric comorbidity in patients with generalized anxiety disorder. Am J Psychiatry. 1993;150(8):1216-1218.
24. Starcevic V, Fallon S, Uhlenhuth EH, Pathak D. Comorbidity rates do not support the distinction between panic disorder and generalized anxiety disorder. Psychopathology. 1994;27(6):269-272.
25. Goisman RM, Goldenberg I, Vasile RG, et al. Comorbidity of anxiety disorders in a multicenter anxiety study. Compr Psychiatry. 1995;36(4):303-311.
26. Zimmerman M, Rothschild L, Chelminski I. The prevalence of DSM-IV personality disorders in psychiatric outpatients. Am J Psychiatry. 2005;162(10):1911-1918.
27. Grant BF, Hasin DS, Stinson FS, et al. Co-occurrence of 12-month mood and anxiety disorders and personality disorders in the US: Results from the national epidemiologic survey on alcohol and related conditions. J Psychiatr Res. 2005;39(1):1-9.
28. Kessler RC. The epidemiology of pure and comorbid generalized anxiety disorder: a review and evaluation of recent research. Acta Psychiatr Scand Suppl. 2000;406:7-13.
29. Bland RC, Newman SC, Orn H. Help-seeking for psychiatric disorders. Can J Psychiatr. 1997;42(9):935-942.
30. Hoge E, Oppenheimer J, Simon N. Generalized anxiety disorder. Focus. 2004;2(3):346-358.
31. Diagnostic and Statistical Manual of Mental Disorders, 3rd ed rev. Washington, DC: American Psychiatric Association; 1987.
32. Wittchen HU, Kessler RC, Beesdo K, Krause P, Holler M, Hoyer J. Generalized anxiety disorder and depression in primary care: prevalence, recognition, and management. J Clin Psychiatry. 2002;63(suppl 8):24-34.
33. Hoehn-Saric R, Hazlett RL, McLeod DR. Generalized anxiety disorder with early and late onset of anxiety symptoms. Compr Anxiety. 1993;34(5):291-298.
34. Keller MB. The long-term clinical course of generalized anxiety disorder. J Clin Psychiatry. 2002;63(suppl 8):11-16.
35. Yonkers KA, Dyck IR, Warshaw M, Keller MB. Factors predicting the clinical course of generalised anxiety disorder. Br J Psychiatry. 2000;176:544-549.
36. Tyrer P, Seivewright H, Johnson T. The Nottingham Study of Neurotic Disorder: predictors of 12-year outcome of dysthymic, panic and generalized anxiety disorder. Psychol Med. 2004;34(8):1385-1394.
37. Yonkers KA, Warshaw MG, Massion AO, Keller MB. Phenomology and course of generalised anxiety disorder. Br J Psychiatry. 1996;168(3):308-313.
38. Souetre E, Lozet H, Cimarosti I, et al. Cost of anxiety disorders: impact of comorbidity. J Psychosom Res. 1994;38(suppl 1):151-160.
39. Walker EA, Roy-Byrne PP, Katon WJ, et al. Psychiatric illness and irritable bowel syndrome: a comparison with inflammatory bowel disease. Am J Psychiatry. 1990;147(12):1656-1661.
40. Lydiard RB, Fossey MD, Marsh W, et al. Prevalence of psychiatric disorders I patients with irritable bowel syndrome. Psychosomatics. 1993;34(3):229-234.
41. Crestani F, Lorez, M, Baer K. Decreased GABAA receptor clustering results in enhanced anxiety and a bias for threat cues. Nat Neurosci. 1999;2(9):833-839.
42. Rickels K, Case WG, Schweizer E. The drug treatment of anxiety and panic disorder. Stress Med. 1988;4(4):231-239.
43. Rocca P, Beoni AM, Eva C, Ferrero P, Zanalda E, Ravizza L. Peripheral benzodiazepine receptor messenger RNA is decreased in lymphocytes of generalized anxiety disorder patients. Biol Psychiatry. 1998;43(10):767-773.
44. Sevy S, Papadimitriou GN, Surmont DW, Goldman S, Mendlewicz J. Noradrenergic function in generalized anxiety disorder, major depressive disorder, and healthy subjects. Biol Psychiatry. 1989;25(2):141-152.
45. Munjack DJ, Baltazar PL, DeQuattro V, et al. Generalized anxiety disorder: some biochemical aspects. Psychiatry Res. 1990;32(1):35-43.
46. Mathew RJ, Ho BT, Francis DJ, Taylor DL, Weinman ML. Catecholamines and anxiety. Acta Psychiatr Scand. 1982;65(2):142-147.
47. Khan A, Lee E, Dager S, et al. Platelet MAO-B activity in anxiety and depression. Biol Psychiatry. 1986;21(8-9):847-849.
48. Tiihonen J, Kuikka J, Rasanen P, et al. Cerebral benzodiazepine receptor binding and distribution in generalized anxiety disorder: a fractal analysis. Mol Psychiatry. 1997;2(6):463-471.
49. Abelson JL, Glitz D, Cameron OG, et al. Blunted growth hormone response to clonidine in patients with generalized anxiety disorder. Arch Gen Psychiatry. 1991;48(2):157-162.
50. Charney DS, Woods SW, Heninger GR. Noradrenergic function in generalized anxiety disorder: effects of yohimbine in healthy subjects and patients with generalized anxiety disorder. Psychiatry Res. 1989;27(2):173-182.
51. Jetty PV, Charney DS, Goddard AW. Neurobiology of generalized anxiety disorder. Psychiatr Clin North Am. 2001;24(1):75-97.
52. Nutt DJ. Neurobiological mechanisms in generalized anxiety disorder. J Clin Psychiatry. 2001;62(suppl 11):22-27.
53. Gray JA. The neuropsychological basis of anxiety. In: Last CG, Hersen M, eds. Handbook of Anxiety Disorders. New York, NY: Pergamon Press; 1988:10-37.
54. Tafet GE, Idoyaga-Vargas VP, Abulafia DP, et al. Correlation between cortisol level and serotonin uptake in patients with chronic stress and depression. Cogn Affect Behav Neurosci. 2001;1(4):388-393.
55. Tafet GE, Toister-Achituv M, Shinitzky M. Enhancement of serotonin uptake by cortisol: a possible link between stress and depression. Cogn Affect Behav Neurosci. 2001;1(1):96-104.
56. Butler PD, Weiss JM, Stout JC, Nemeroff CB. Corticotropin-releasing factor produces fear-enhancing and behavioral activating effects following infusion into the locus coeruleus. J Neurosci. 1990;10(1):176-183.
57. Griebel G. Is there a future for neuropeptide receptor ligands in the treatment of anxiety disorders? Pharmacol Ther. 1999;82(1):1-61.
58. Koob GF, Gold LH. Molecular biological approaches in the behavioural pharmacology of anxiety and depression. Behav Pharmacol. 1997;8(7):652.
59. Noyes R Jr, Clarkson C, Crowe RR, Yates WR, McChesney CM. A family study of generalized anxiety disorder. Am J Psychiatry. 1987;144(8):1019-1024.
60. Skre I, Onstad S, Edvardsen J, Torgersen S, Kringlen E. A family study of anxiety disorders: familial transmission and relationship to mood disorder and psychoactive substance use disorder. Acta Psychiatr Scand. 1994;90(5):366-374.
61. Andrews G, Stewart G, Allen R, Henderson AS. The genetics of six neurotic disorders: a twin study. J Affect Disord. 1990;19(1):23-29.
62. Ohara K, Suzuki Y, Ochiai M, Tsukamoto T, Tani K, Ohara K. A variable-number-tandem-repeat of the serotonin transporter gene and anxiety disorders. Prog Neuropsychopharmacol Biol Psychiatry. 1999;23(1):55-65.
63. Mahe V, Balogh A. Long-term pharmacological treatment of generalized anxiety disorder. Int Clin Psychopharmacol. 2000;15(2):99-105.
64. Pollack MH. Optimizing pharmacotherapy of generalized anxiety disorder to achieve remission. J Clin Psychiatry. 2001;62(suppl 19):20-25.
65. Shader RI, Greenblatt DJ. Use of benzodiazepines in anxiety disorders. N Engl J Med. 1993;328(19):1398-1405.
66. Dubovsky SL. Generalized anxiety disorder: new concepts and psychopharmacologic therapies. J Clin Psychiatry. 1990;51(suppl):3-10.
67. Sadock BJ, Sadock VA. Biological therapies. In: Sadock BJ, Sadock VA, eds. Synopsis of Psychiatry: Behavioral Sciences/Clinical Psychiatry. Baltimore, MD: Lippincott, Williams & Wilkins; 1991:907-911.
68. Ballenger J. Current treatment of the anxiety disorders in adults. Biol Psychiatry. 1999;46(11):1579-1594.
69. Rickels K, Downing R, Winokur A. Long-term diazepam therapy and clinical outcome. JAMA. 1983;250(6):767-771.
70. Hollister LE, Conley FK, Britt RH, Shuer L. Long-term use of diazepam. JAMA. 1981;246(14):1568-1570.
71. Rickels K, Downing R, Schweizer E, Hassman H. Antidepressants for the treatment of generalized anxiety disorder. A placebo-controlled comparison of imipramine, trazodone, and diazepam. Arch Gen Psychiatry. 1993;50(11):884-895.
72. Hoehn-Saric R, McLeod DR, Zimmerli WD. Differential effects of alprazolam and imipramine in generalized anxiety disorder: somatic versus psychic symptoms. J Clin Psychiatry. 1988;49(8):293-301.
73. Balon R, Mufti R, Arfken C. A survey of prescribing practices for monoamine oxidase inhibitors. Psychiatr Serv. 1999;50(7):945-947.
74. Wingerson D, Nguyen C, Roy-Byrne PP. Clomipramine treatment for generalized anxiety disorder. J Clin Psychopharmacol. 1992;12(3):214-215.
75. Rocca P, Fonzo V, Scotta M, Zanalda E, Ravizza L. Paroxetine efficacy in the treatment of generalized anxiety disorder. Acta Psychiatr Scand. 1997;95(5):444-450.
76. Bellew KM, McCafferty JP, Iyengar M, et al. Paroxetine treatment of GAD: A double blind, placebo-controlled trial. Presented at: the 153rd Annual Meeting of the American Psychiatric Association; May 13-18, 2000; Chicago.
77. Pollack MH, Zaninelli R, Goddard A, et al. Paroxetine in the treatment of generalized anxiety disorder: results of a placebo controlled, flexible-dosage trial. J Clin Psychiatry. 2001;62(5):350-357.
78. Lenze EJ, Mulsant BH, Shear MK, et al. Efficacy and tolerability of citalopram in the treatment of late-life anxiety disorders: results from an 8-week randomized, placebo-controlled trial. Am J Psychiatry. 2005;162(1):146-150.
79. Davidson JR, Bose A, Korotzer A, Zheng H. Escitalopram in the treatment of generalized anxiety disorder: double-blind, placebo controlled flexible-dose study. Depress Anxiety. 2004;19(4):234-240.
80. Ball SG, Kuhn A, Wall D, Shekhar A, Goddard AW. Selective serotonin reuptake inhibitor treatment for generalized anxiety disorder: a double-blind, prospective comparison between paroxetine and sertraline. J Clin Psychiatry. 2005;66(1):94-99.
81. Davidson JR, DuPont RL, Hedges D, Haskins JT. Efficacy, safety, and tolerability of venlafaxine extended release and buspirone in outpatients with generalized anxiety disorder. J Clin Psychiatry. 1999;60(8):528-535.
82. Rickels K, Pollack MH, Sheehan DV, Haskins JT. Efficacy of extended-release venlafaxine in non-depressed outpatients with generalized anxiety disorder. Am J Psychiatry. 2000;157(6):968-974.
83. Nimatoudis I, Zissis NP, Kogeorgos J, Theodoropoulou S, Vidalis A, Kaprinis G. Remission rates with venlafaxine extended release in Greek outpatients with generalized anxiety disorder. A double-blind, randomized, placebo controlled study. Int Clin Psychopharmacol. 2004;19(6):331-336.
84. Gelenberg A, Lydiard RB, Rudolph R, Aguiar L, Haskins JT, Salinas E. Efficacy of venlafaxine extended-release capsules in nondepressed outpatients with generalized anxiety disorder: A 6-month randomized controlled trial. JAMA. 2000;283(23):3082-3088.
85. Allgulander C, Hackett D, Salinas E. Venlafaxine extended release (ER) in the treatment of generalised anxiety disorder: twenty-four-week placebo-controlled dose-ranging study. Br J Psychiatry. 2001;179:15-22.
86. Hedges DW, Reimherr FW, Strong RE, Halis CH, Rust C. An open trial of nefazodone in adult patients with generalized anxiety disorder. Psychopharmacol Bull. 1996;32(4):671-676.
87. Goodnick PJ, Puig A, DeVane CL, Freund BV. Mirtazapine in major depression with comorbid generalized anxiety disorder. J Clin Psychiatry. 1999;60(7):446-448.
88. DeMartinis N, Rynn M, Rickels K, Mandos L. Prior benzodiazepine use and buspirone response in the treatment of generalized anxiety disorder. J Clin Psychiatry. 2000;61(2):91-94.
89. Apter J, Allen L. Buspirone: future directions. J Clin Psychopharmacol. 1999;19(1):86-93.
90. Ferreri M, Hantouche EG, Billardon M. Value of hydroxyzine in generalized anxiety disorder: controlled double blind study versus placebo. Encephale. 1994;29(6):785-791.
91. Llorca PM, Spadone C, Sol O, et al. Efficacy and safety of hydroxyzine in the treatment of generalized anxiety disorder: a 3-month double-blind study. J Clin Psychiatry. 2002;63(11):1020-1027.
92. Lader M, Scotto JC. A multicentre doubleblind comparison of hydroxyzine, buspirone and placebo in patients with generalized anxiety disorder. Psychopharmacology (Berl). 1998;139(4):402-406.
93. Uebelhaek R, Franke L, Schewe HJ. Inhibition of platelet MAO-B by kava pyrone-enriched extract from Piper methysticum Forster (kava-kava). Pharmacopsychiatry. 1998;31(5):187-92.
94. Boerner R, Sommer J, Berger W, Kuhn U, Schmidt U, Mannel M. Kava-kava extract li 150 is as effective as opipramol and buspirone in generalized anxiety disorder-an 8 week randomized, double blind multicentre clinical trial in 129 outpatients. Phytomedicine. 2003;10(suppl 4):38-49.
95. Connor KM, Davidson JR. A placebo-controlled study of kava kava in generalized anxiety disorder. Int Clin Psychopharmacol. 2002;17(4):185-188.
96. Borkovec TD, Costello E. Efficacy of applied relaxation and cognitive-behavioral therapy in the treatment of generalized anxiety disorder. J Consult Clin Psychol. 1993;61(4):611-619.
97. Butler G, Fennell M, Robson P, Gelder M. Comparison of behavior therapy and cognitive behavior therapy in the treatment of generalized anxiety disorder. J Consult Clin Psychol. 1991;59(1):167-175.